Compare Docusign Inc (DOCU) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Docusign Inc trades at $59.42 (market cap $11.33B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Docusign Inc nearer its low. Which is the better fit depends on your goals.
| DOCU | XBI | |
|---|---|---|
Market Cap | $11.33B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $85.01 | $164.28 |
52-Week Low | $41.75 | $86.92 |
Enterprise Value | $10.70B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $57.82, down 3.05% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.09 exceeding the $0.994 estimate. Revenue growth remains steady, reaching $2.98B in 2025, while profitability improved significantly with a net income margin of 35.87%. Recent news highlights institutional trading activity and positive analyst coverage on growth prospects.
The outlook for DOCU is mixed; fundamentals show robust revenue growth and expanding margins, but valuation multiples like a P/E of 38.53 suggest premium pricing. Key risks include competitive pressures in e-signature software and reliance on subscription revenue. Analyst consensus is cautious with a hold-heavy rating, though the $55.40 price target implies limited upside from current levels.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
